Comparison of the effect of VOSO4, Na3VO4 and NaVO3 on proliferation, viability and morphology of H35-19 rat hepatoma cell line

Polish Journal of Pathology

Volumn 58, Issue 1, 2007, Pages 51-57

  Kordowiak, Anna M ^a   Klein, Andrzej ^a   Goc, Anna ^a   Da̧broś, Wojciech ^b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CRYSTAL VIOLET; NEUTRAL RED; VANADATE SODIUM; VANADIC ACID; VANADIUM DERIVATIVE; VANADYL SULFATE; ANTIDIABETIC AGENT;

ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; CELL DAMAGE; CELL ORGANELLE; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CYTOTOXICITY; ELECTRON MICROSCOPY; GROWTH INHIBITION; HEPATOMA CELL; NONHUMAN; RAT; ANIMAL; CELL SURVIVAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; LIVER CELL CARCINOMA; METABOLISM; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOGLYCEMIC AGENTS; MICROSCOPY, ELECTRON, TRANSMISSION; RATS; VANADATES; VANADIUM COMPOUNDS;

EID: 34248644614     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Aharon Y, Mevorach M, Shamoon H: Vanadyl sulphate does not enhance insulin action in patients with type 1 diabetes. Diabetes Care 1998, 21, 2194-219.
2. Almedeida M, Filipe S, Hunianes S, Mala MF, Melo R, Severino N, Silva JA, Freesto da Silva JJ, Wever R: Vanadium haloperoxidases from brown algae of the Laminaridacae family. Phytochemistry 2001, 52, 633-642.
3. Azay J, Bres M, Krośniak P, Teissedre L, Cabanis JC, Serrano JJ, Cros G: Vanadium pharmacokinetics and oral bioavailability upon single-dose administration of vanadyl sulphate to rats. Blackwell Sci Fund Clin Pharmacol 2001, 15, 313-324.
4. Ban J, Maysinger D, Kovač V, Galetić I, Matulić M, Hadžija M, Užarević B: Molecular mechanisms involved in the antiproliferative action of protein tyrosine phosphatase inhibitor potassium bisperoxo (1,10-phenanthroline)oxovanadate. Life Sciences 2000, 68, 65-175.
5. Borenfreund E, Puerner JA: Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett 1985, 24, 119-124.
6. Capella LS, Gefe MR, Silva EF, Affonso-Mitidieri O, Lopes AG, Rumjanek VM, Capella MAM: Mechanisms of vanadate induced cellular glutathione and NADPH. Arch Biochem Biophys 2002, 406, 65-72.
7. Da̧broś W, Goc A, Klein A, Kordowiak AM: Morphology and some biochemical properties of rat hepatoma cell line H35-19 after vanadyl sulphate action, The 14th International Symposium of Polish Network of Molecular and Cellular Biology UNESCO/PAS. Molecular and Physiological Aspects of Regulatory Processes of the Organism. 2-3 June Cracow 2005, Abstracts pp. 87-89.
8. DeCremer K, VanHulle M, Cherry C, Cornelis R, Strijckmansk K, Dams R, Lameire N, Vanholder R: Fractionation of vanadium complexes in serum, packed cells and tissues of Wistar rats by means of gel filtration and anion-exchange chromatography J Biol Inorg Chem 2002, 7, 884-890.
9. Ding M, Li JJ, Leonard SS, Ye JP, Shi X, Colborn NH, Castronowa V, Vallyathan V: Vanadate-induced activation of activator protein 1: role of reactive oxygen species. Carcinogenesis 1999, 20, 663-668.
10. Domingo JL: Vanadium: a review of the reproductive and developmental toxicology. Reprod Toxicol 1996, 10, 175-182.
11. Domingo JL: Vanadium and diabetes. What about vanadium toxicity. Mol Cell Biochem 2000, 203, 185-187.
12. Evangelou A, Karkabounas S, Kalpouzos G, Malamas M, Liasko R, Stefanou D, Vlahos AT, Kabanos TA: (1997) Comparison of the therapeutic effects of two vanadium complexes administered at low doses on benzo[a]pyrene-induced malignant tumors in rats. Cancer Letters 1997, 119, 221-225.
13. Fawcett JP, Farquhar SJ, Thou T, Shand BI: Oral vanadyl sulphate docs not affect blood cells viscosity or biochemistry in humans. Pharmacol Toxicol 1997, 80, 202-206.
14. French RJ, Jones PJH: Role of vanadium in nutrition: metabolism, essentiality and dietary considerations Life Sci.1993, 52, 339-346.
15. Gillies RJ, Didier N, Denton M: Determination of cell number in monolayer cultures Anal Biochem 1986, 159, 109-113.
16. Goldfine AB, Patti ME, Zuberi L, Goldstein BJ, LeBlanc R, Landaker EJ, Jiang Z, Willsky GR, Kahn CR: Metabolic effects of vanadyl sulphate in humans with non-insulin-dependent diabetes mcllitus: in vivo and in vitro studies. Metabolism 2000, 49, 400-410.
17. Ivancsits S, Pilger A, Diem E, Schaffer A, Rudiger HW: Vanadate induces DNA strand breaks in cultured human fibroblasts at doses relevant to occupation exposure. Mutation Research 2002, 519, 25-35.
18. Karnovsky MJ: A formaldehyde-glutaraldehyde fixative of high osmolarity for use in electron microscopy. J Cell Biol 1965, 27, 137A-138A.
19. Khendelwal RL, Pugazhenthi S: Vanadium as a potential therapeutic agent for the treatment of diabetic mellitus. In Callery P, Corbella J, Domingo JL, Ethienne JC, Llobet JM, Libbey J, (eds) Metal Ions in Biology and Med 1996 vol. 4 pp. 673-675: Eurotext Paris.
20. th International Symposium of Polish Network of Molecular and Cellular Biology UNESCO/PAS. Molecular and Physiological Aspects of Regulatory Processes of the Organism. 1-2 June 2006, Cracow Abstracts pp 328-330.
21. Molinuevo MS, Barrio DA, Cortizo AM, Etcheverry SB: Antitumoral properties of two new vanadyl(IV) complexes in culture: role of apoptosis and oxidative stress. Cancer Chemother Pharmacol 2004, 53, 163-172.
22. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytoxicity assays. J Immunol Methods 1983, 65, 55-63.
23. Mukherjee B, Patra B, Mahapatra S, Banerjee P, Amit Tiwari, Chatterjee M: Vanadium- an element of atypical biological significance Toxicology Letters 2004, 150, 135-143.
24. Poucheret P, Verma S, Grynpas MD, McNeill JH: Vanadium and diabetes. Mol Cell Biochem 1998, 188, 73-80.
25. Pugazhenthi S, Khendelwal RL: Insulin-like effects of vanadate on hepatic glycogen metabolism in nondiabetic and streptozotocin-induced diabetic rats. Diabetes 1990, 39, 821-827.
26. Rodríguez-Mercado JJ, Roldán-Reyes E, Altamirano-Lozano M: Genotoxic effects of vanadium (IV) in human peripheral blood cells. Toxicology Letters 2003, 144, 359-369.
27. Semiz S, McNeill JH: Oral treatment with vanadium of Zucker fatty rats activates muscle glycogen synthesis and insulin-stimulated protein phosphatases-1 activity. Mol Cell Biochem 2002, 236, 123-131.
28. Shafrir E, Spielman S, Nachliel I, Khamaisi M, Bar-On H, Ziv E: Treatment of diabetes with vanadium salts: general overview and amelioration of nutritionally induced diabetes in the Psammomys obescs gerbil. Diabetes Metab Res Rev 2001, 17, 55-66.
29. Shechter Y: Insulin-mimetic effects of vanadate. Possible implications for further treatment of diabetes. Diabetes 1990, 39, 1-5.
30. Shi X, Hudson LG, Liu KJ: Oxidative stress and apoptosis in metal ion-induced carcinogenesis. Free Radical Biol. Med.2004, 37, 582-593.
31. Thompson KH, Leichter J, McNeill JH: Studies of vanadyl sulphate as a glucose-lowering agent in STZ-diabetic rats. Biochem Biophys Res Commun 1993, 197, 1549-1555.
32. Tsiani E, Fantus JG: Vanadium compounds. Biological actions and potential as pharmacological agents. Trends Endocrinol Metab1997, 8, 51-58.
33. Venable JH, Coggeshall RA: Simplified lead citrate stain for use in electron microscopy. J Cell Biol 1965, 25, 407-408.
34. Wozniak K, Blasiak J: Vanadyl sulfate can differentially damage DNA in human lymphocytes and Hela Wells. Arch. Toxicol. 2004, 78, 7-15.
35. Zhang Z, Gao N, He H, Huang C, Luo J. Shi X: Vanadate activated Akt and promoted S phase entry. Mol Cell Biochem 2004, 255, 227-237.
36. Zhang Z, Huang C, Li J, Leonard SS, Lanciotti R, Butterworth L, Shi X: Vanadate-induced cell growth regulation and the role of reactive oxygen species. Arch Biochem Biophys 2001, 392, 311-320.
37. Zhang Z, Huang C, Li J, Shi X: Vanadate-induced cell growth arrest is p53-dependent through activation of p21 in C141 cells. J. Inorg. Biochem 2002, 89, 142-148.